Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings

por Inusa, Baba Psalm Duniya, Atoyebi, Wale, Hassan, Abdul Aziz, Idhate, Tushar, Dogara, Livingstone, Ijei, Ifeoma, Qin, Yewen, Anie, Kofi, Lawson, Juliana Olufunke, Hsu, Lewis
Publicado 2018

A Multi-centre Survey of Acceptability of Newborn Screening for Sickle Cell Disease in Nigeria

por Nnodu, Obiageli E, Adegoke, Samuel A, Ezenwosu, Osita U, Emodi, Ifeoma I, Ugwu, Ngozi I, Ohiaeri, Chinatu N, Brown, Biobele J, Olaniyi, John A, Isa, Hezekiah, Okeke, Chinedu C, Bene, Benard A, Balogun, Modupe T, Okocha, Emmanuel C, Aneke, John C, Lawson, Juliana Olufunke J, Usman, Abjah M, Diaku-Akinwumi, Ijeoma N, Okolo, Angela A, Israel-Aina, Yetunde T, Jamda, Mustapha, Aworanti, Oladapo W, Piel, Frédéric B, Adekile, Adekunle D
Publicado 2018